Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

39.67 +0.81 (+2.08%)
Streaming Delayed Price Updated: 3:14 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
7 Biotech Stocks to Buy on the Dip: June 2024 ↗
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
News headline image
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
NASDAQ:RPRX: good value for what you're paying. ↗
Investors should take notice ofROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
Looking Into Royalty Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
NASDAQ:RPRX is an undervalued gem with solid fundamentals. ↗
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? ↗
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval. 
Via Benzinga
News headline image
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out ↗
The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug. 
Via Investor's Business Daily
News headline image
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe ↗
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion. 
Via Benzinga
News headline image
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
From Royalty Pharma plc; Cytokinetics
Via GlobeNewswire
News headline image
7 Dividend Stocks to Buy at a 52-Week Low ↗
For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low. 
Via InvestorPlace
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024 ↗
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Royalty Pharma Reports First Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment ↗
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses... 
Via Benzinga
News headline image
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Second Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Pharma Stocks to Sell in April Before They Crash & Burn ↗
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside. 
Via InvestorPlace
News headline image
Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of) ↗
These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio. 
Via InvestorPlace
News headline image
April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio ↗
Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April. 
Via InvestorPlace
News headline image
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio ↗
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider. 
Via InvestorPlace
News headline image
For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals. ↗
When you look at ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months ↗
Analysts are quite bullish about these beaten-down stocks. 
Via The Motley Fool
News headline image
Royalty Pharma Reports Q4 and Full Year 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.